BioStock: BioInvent comments on breast cancer study progress - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Nyhetsbrev: Miljonärernas framgångsrecept – så investerar de rikaste / Lönelistan avslöjad: Sveriges bäst betalande företag

Pressmeddelande

BioStock: BioInvent comments on breast cancer study progress

Cision Publicerad: 13 Dec 2023 09:08
Bioinvent

BioInvent’s pipeline consists of five drug candidates advancing through six clinical trials. During the San Antonio Breast Cancer Symposium, BioInvent presented the first clinical data from one of these – the phase I/IIa trial of its second FcyRIIB-blocking antibody BI-1607. BioStock reached out to BioInvent’s Chief Medical Officer Andres McAllister for a comment.

Read the article at biostock.se:

https://www.biostock.se/en/2023/12/bioinvent-comments-on-breast-cancer-study-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Bioinvent

Läses av andra just nu

Om aktien Bioinvent

Senaste nytt